The European Commission has approved JASCAYD (nerandomilast) for use in the European Union as a new oral treatment option for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The decision brings a novel therapy to patients in the bloc facing serious lung diseases that steadily worsen breathing and quality of life.
According to the announcement, JASCAYD is the first oral preferential PDE4B inhibitor cleared in the EU. Its mechanism is described as having both antifibrotic and immunomodulatory effects, giving it a different treatment profile from existing approaches used in fibrotic lung disease.
The approval is significant because IPF and PPF affect more than 500,000 people across Europe. These conditions lead to permanent scarring in the lungs, limiting how well patients can breathe and underscoring the need for additional therapies that may help manage disease progression.
The decision follows Phase III FIBRONEER trials referenced in the company announcement. While the trimmed release does not include full study details, the EU authorization marks an important regulatory milestone for nerandomilast and expands treatment options for people living with fibrotic interstitial lung diseases in Europe.
